Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
63.70    -2.50 (-3.78%)
Bid:
63.40
Ask:
63.70
Spread: 0.30 (0.473%)
Market Cap: £562.74m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Portfolio co First Light completes $45m fund raise

14 Feb 2022 07:00

RNS Number : 5012B
IP Group PLC
14 February 2022
Β 

FOR RELEASE ON

14 February 2022

Β 

Β 

IP Group plc - Portfolio company First Light Fusion

completes $45m (Β£33m*) fund raise

Β 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that portfolio company First Light Fusion Ltd, a global leader in researching energy generation via inertial fusion, has completed its Series C fund raise, raising $45m (Β£33m*) from both existing and new investors.

Β 

As announced on 29 November 2021, IP Group committed Β£5m to the funding round and, following completion, has an undiluted beneficial holding of 27.4%. IP Group has recorded a net unrealised fair value gain of Β£27.2m** or 3p per share.

Β 

The round was also supported by existing investors Oxford Science Enterprises (formerly OSI) and Hostplus as well as new investors Braavos Capital and Tencent.

Β 

First Light's approach to fusion, which is safe, clean, and a virtually limitless source of energy, has the potential to transform the world's energy system. Unlike existing nuclear, there is no long-lived waste, no meltdown risk, and raw materials can be found in abundance. Unlike many other fusion approaches, First Light's power plant will largely leverage existing technology and materials.

The new funding will be used to accelerate the development of First Light's "gain" experiment, whereby the amount of energy generated outstrips that used to spark the reaction, and to perform further design and engineering work on a 'first of a kind' commercial fusion energy power plant based on its technology.

Β 

*GBP equivalent using 1.36 USD/GBP

**Fair value gains are quoted net of the Group's long-term incentive carry scheme ('LTICS').Β 

Β 

Β 

For more information, please contact:

Β 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

Β 

Notes for editors

Β 

About IP Group

Β 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

Β 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

Β 

For more information, please visit our website at www.ipgroupplc.com.

Β 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCBKDBKFBKDOBD
Date   Source Headline
3rd Jun 20267:00 amRNSHolding(s) in Company
2nd Jun 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
29th May 20267:00 amRNSHolding(s) in Company
28th May 20267:00 amRNSHolding(s) in Company
13th May 20265:30 pmRNSNotice of AGM
12th May 20269:10 amRNS-REnterprise reports positive results from P2 trial
11th May 20264:25 pmRNSHolding(s) in Company
11th May 20264:19 pmRNSHolding(s) in Company
7th May 20267:00 amRNSAppointment of Chair Designate
23rd Apr 202612:18 pmRNSDirector/PDMR Shareholding
21st Apr 20267:00 amRNS-RFirst Light announces £25m successful first close
15th Apr 20265:00 pmRNSAnnual Financial Report
14th Apr 20269:25 amRNSHolding(s) in Company
30th Mar 20262:00 pmRNSNew climate fund launch with Australia's CEFC
26th Mar 202610:00 amRNSHolding(s) in Company
25th Mar 20262:00 pmRNSHolding(s) in Company
19th Mar 20265:30 pmRNSHolding(s) in Company
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
17th Mar 20267:00 amRNSIP Group plc 2025 Annual Results Release
13th Mar 20265:45 pmRNSHolding(s) in Company
12th Mar 202611:00 amRNSHolding(s) in Company
12th Mar 20269:00 amRNSNotice of Results
12th Mar 20269:00 amRNSNotice of Results
4th Mar 20267:00 amRNS-RPortfolio company Oxa raises $103m in Series D
26th Feb 20262:53 pmRNSHolding(s) in Company
26th Feb 20269:30 amRNSHolding(s) in Company
25th Feb 20265:51 pmRNSHolding(s) in Company
11th Feb 20269:01 amRNS-RMicrobiotica announces positive P1b trial results
30th Jan 20267:00 amRNSHolding(s) in Company
29th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 202612:36 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSDirectorate change
14th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20266:25 pmRNSHolding(s) in Company
7th Jan 20262:06 pmRNSPulmocide announces termination of Phase 3 study
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
18th Dec 20254:13 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20255:26 pmRNSHolding(s) in Company
4th Dec 20254:13 pmRNSHolding(s) in Company
1st Dec 20255:37 pmRNSTotal Voting Rights
20th Nov 20257:00 amRNSCompletion of share buyback programme
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20251:10 pmRNSArtios completes oversubscribed $115m financing
14th Nov 20255:47 pmRNSTransaction in Own Shares
14th Nov 20258:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.